Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENVEC files S-1 -- Ignore unavailable to you. Want to Upgrade?

To: Labrador who wrote (28)	12/1/2009 10:13:24 AM
From: Gary Mohilner	Read Replies (1) \| Respond to of 30

I believe that the shares are still seriously under priced and that the increase in share price is very justified by the fact that the longer the PACT trial goes without the 184th event, the better the data. There is no doubt in my mind that the data warrants approval, the only question is whether they can do it on the strength of the data at 184 events, or the trial must go to conclusion. While I don't believe you'll see the shares fall below $1, the stock is subject to manipulation, so anything's possible. Personally I believe that $2 to $4 is possible prior to a partnership announcement, and much higher, depending on the terms of the partnership, after it's announced. There are many companies with drugs in trial where data's far weaker then what's being produced by TNFerade where the share price is dramatically higher. I'll irritate some people by saying that Provenge, which I believe will be approved, is weaker and will ultimately have a much smaller market then TNFerade, is one of them. Gary